CA3129057C - Methode de purification des proteines - Google Patents
Methode de purification des proteines Download PDFInfo
- Publication number
- CA3129057C CA3129057C CA3129057A CA3129057A CA3129057C CA 3129057 C CA3129057 C CA 3129057C CA 3129057 A CA3129057 A CA 3129057A CA 3129057 A CA3129057 A CA 3129057A CA 3129057 C CA3129057 C CA 3129057C
- Authority
- CA
- Canada
- Prior art keywords
- hemopexin
- haptoglobin
- composition
- transferrin
- total protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Marine Sciences & Fisheries (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne, dune manière générale, une méthode de purification des protéines. Plus précisément, il est décrit une méthode de purification de lhaptoglobine et de lhémopexine provenant de la même matière première, et des utilisations associées.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261709342P | 2012-10-03 | 2012-10-03 | |
US61/709,342 | 2012-10-03 | ||
US13/803,525 US9534029B2 (en) | 2012-10-03 | 2013-03-14 | Method of purifying proteins |
US13/803,525 | 2013-03-14 | ||
AU2013203930 | 2013-04-11 | ||
AU2013203930A AU2013203930B2 (en) | 2012-10-03 | 2013-04-11 | A method of purifying proteins |
EP13170202 | 2013-06-03 | ||
EP13170202.9 | 2013-06-03 | ||
CA2886726A CA2886726C (fr) | 2012-10-03 | 2013-10-01 | Methode de purification des proteines |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2886726A Division CA2886726C (fr) | 2012-10-03 | 2013-10-01 | Methode de purification des proteines |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3129057A1 CA3129057A1 (fr) | 2014-04-10 |
CA3129057C true CA3129057C (fr) | 2023-03-07 |
Family
ID=52824845
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2886726A Active CA2886726C (fr) | 2012-10-03 | 2013-10-01 | Methode de purification des proteines |
CA3129057A Active CA3129057C (fr) | 2012-10-03 | 2013-10-01 | Methode de purification des proteines |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2886726A Active CA2886726C (fr) | 2012-10-03 | 2013-10-01 | Methode de purification des proteines |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2904005A1 (fr) |
JP (2) | JP6370792B2 (fr) |
KR (2) | KR102125695B1 (fr) |
CN (2) | CN112717125A (fr) |
CA (2) | CA2886726C (fr) |
HK (1) | HK1212995A1 (fr) |
SG (1) | SG11201501921SA (fr) |
WO (1) | WO2014055552A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2887588T3 (es) * | 2015-08-13 | 2021-12-23 | Kamada Ltd | Composiciones derivadas de pasta de fracción de Cohn y uso de las mismas |
JPWO2017170597A1 (ja) * | 2016-03-29 | 2019-02-14 | 協和発酵キリン株式会社 | 血中でハプトグロビンに結合して多価の免疫複合体を形成する抗体を有効成分とする自己免疫疾患治療剤 |
SG11202000210UA (en) * | 2017-08-08 | 2020-02-27 | Csl Behring Ag | Hemopexin formulations |
JP6600123B1 (ja) * | 2018-04-18 | 2019-10-30 | 積水メディカル株式会社 | ヘモグロビン分析方法 |
CA3138650A1 (fr) | 2019-05-17 | 2020-11-26 | Universitaet Zuerich | Haptoglobine destinee a etre utilisee dans le traitement d'un evenement neurologique secondaire indesirable suite a un avc hemorragique |
CN117136068A (zh) | 2021-02-01 | 2023-11-28 | 瑞士杰特贝林生物制品有限公司 | 治疗或预防出血性中风后不良继发性神经学后果的方法 |
US20240034749A1 (en) * | 2021-02-04 | 2024-02-01 | Green Cross Corporation | Method for purification of hemopexin and haptoglobin |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5337406B2 (fr) * | 1973-11-15 | 1978-10-09 | ||
GB1426039A (en) * | 1973-11-15 | 1976-02-25 | Green Cross Corp | Haptoglobin in aqueous solution and process for tits preparation |
US4129648A (en) * | 1977-11-21 | 1978-12-12 | Collier Harry O J | Method for reducing endogenous prostaglandin synthesis |
US4764369A (en) | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
JPS6317899A (ja) * | 1986-07-09 | 1988-01-25 | Green Cross Corp:The | ハプトグロビンの精製方法 |
JPH01305036A (ja) * | 1988-05-31 | 1989-12-08 | Green Cross Corp:The | 血漿蛋白成分の加熱処理方法および血漿蛋白成分製剤 |
US5169936A (en) * | 1989-04-14 | 1992-12-08 | Biogen, Inc. | Protein purification on immobilized metal affinity resins effected by elution using a weak ligand |
US5138034A (en) * | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
FR2672604B1 (fr) * | 1991-02-07 | 1995-05-05 | Pasteur Merieux Serums Vacc | Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue. |
SE9301582D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Purification of plasma proteins |
DE19830914C1 (de) * | 1998-07-10 | 1999-06-24 | Centeon Pharma Gmbh | Verfahren zur Herstellung einer Proteinlösung |
US6093804A (en) * | 1998-09-24 | 2000-07-25 | American National Red Cross | Method for purification of alpha-1 proteinase inhibitor |
US6815181B2 (en) * | 2001-07-09 | 2004-11-09 | Applera Corporation | Nucleic acid molecules encoding human secreted hemopexin-related proteins |
DE10211632A1 (de) | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration |
DE10215315A1 (de) * | 2002-04-05 | 2003-11-20 | Aventis Behring Gmbh Intellect | Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels |
AU2002307776A1 (en) * | 2002-04-16 | 2003-10-27 | Kamada Ltd. | Ultrapure transferrin for pharmaceutical compositions |
DE10261126A1 (de) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
JP2004224793A (ja) * | 2003-01-17 | 2004-08-12 | Research Corp Technologies Inc | 子宮内膜症の治療方法 |
JP2004256463A (ja) * | 2003-02-26 | 2004-09-16 | Univ Waseda | 多形核白血球の細胞接着抑制剤及び細胞接着抑制方法 |
GB0423196D0 (en) * | 2004-10-19 | 2004-11-24 | Nat Blood Authority | Method |
US7291338B2 (en) * | 2005-03-09 | 2007-11-06 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
JP2009537812A (ja) * | 2006-05-15 | 2009-10-29 | デジラブ インコーポレーテッド | 2型糖尿病プリフォームのバイオマーカー、及び2型糖尿病プリフォームの存在又は不在を検出する方法 |
CN101778860B (zh) * | 2007-08-17 | 2013-07-10 | Csl百灵有限公司 | α-1-抗胰蛋白酶和载脂蛋白A-I的纯化方法 |
EP2027875A1 (fr) * | 2007-08-23 | 2009-02-25 | Octapharma AG | Processus d'isolation et de purification d'une protéine cible libre de protéine de prion (PrPSC) |
KR101426039B1 (ko) * | 2008-09-11 | 2014-08-01 | 삼성테크윈 주식회사 | 얼굴/물체 인식을 위한 특징점 검출 장치 및 방법 |
FR2942233B1 (fr) * | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
EP2236617A1 (fr) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Procédés de stérilisation de terminal de compositions biofonctionnelles |
WO2011002070A1 (fr) * | 2009-07-02 | 2011-01-06 | 協和発酵キリン株式会社 | Composition pharmaceutique pour le traitement de troubles ou maladies de surcharge en fer, grâce à laquelle la réduction de concentration en fer est efficace, et qui comprend la protéine gdf7/bmp12 |
WO2011007208A1 (fr) * | 2009-07-16 | 2011-01-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Composés et procédés pour le traitement du cancer |
ES2360782B1 (es) * | 2009-07-28 | 2012-03-12 | Grifols, S.A. | Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos. |
CN102471368A (zh) * | 2009-08-11 | 2012-05-23 | 拜康有限公司 | 色谱方法及其纯化的化合物 |
DK2947148T3 (en) * | 2010-04-20 | 2017-09-18 | Octapharma Ag | NEW STABILIZER FOR PHARMACEUTICAL PROTEINS |
WO2012050874A2 (fr) * | 2010-09-28 | 2012-04-19 | Soares Miguel P | Ciblage de l'hème pour le traitement de maladies inflammatoires à médiation immunitaire |
-
2013
- 2013-10-01 CN CN202110206879.5A patent/CN112717125A/zh active Pending
- 2013-10-01 KR KR1020157011544A patent/KR102125695B1/ko active IP Right Grant
- 2013-10-01 CN CN201380051960.4A patent/CN104968676A/zh active Pending
- 2013-10-01 KR KR1020207017157A patent/KR102231613B1/ko active IP Right Grant
- 2013-10-01 EP EP13777203.4A patent/EP2904005A1/fr not_active Withdrawn
- 2013-10-01 WO PCT/US2013/062916 patent/WO2014055552A1/fr active Application Filing
- 2013-10-01 JP JP2015535745A patent/JP6370792B2/ja active Active
- 2013-10-01 CA CA2886726A patent/CA2886726C/fr active Active
- 2013-10-01 CA CA3129057A patent/CA3129057C/fr active Active
- 2013-10-01 SG SG11201501921SA patent/SG11201501921SA/en unknown
-
2016
- 2016-01-26 HK HK16100830.6A patent/HK1212995A1/zh unknown
-
2018
- 2018-07-10 JP JP2018130335A patent/JP6876655B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR20150063547A (ko) | 2015-06-09 |
JP6370792B2 (ja) | 2018-08-08 |
CA2886726A1 (fr) | 2014-04-10 |
JP6876655B2 (ja) | 2021-05-26 |
CA2886726C (fr) | 2021-11-23 |
KR102125695B1 (ko) | 2020-06-24 |
CA3129057A1 (fr) | 2014-04-10 |
KR102231613B1 (ko) | 2021-03-25 |
EP2904005A1 (fr) | 2015-08-12 |
CN112717125A (zh) | 2021-04-30 |
JP2018172426A (ja) | 2018-11-08 |
SG11201501921SA (en) | 2015-04-29 |
CN104968676A (zh) | 2015-10-07 |
KR20200075027A (ko) | 2020-06-25 |
HK1212995A1 (zh) | 2016-06-24 |
WO2014055552A1 (fr) | 2014-04-10 |
JP2015532301A (ja) | 2015-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10918696B2 (en) | Methods of treatment using hemopexin compositions | |
CA3129057C (fr) | Methode de purification des proteines | |
EP1268551B1 (fr) | Procede de production d'igg | |
CN106459140B (zh) | 用于纯化免疫球蛋白的方法 | |
AU2001273907A1 (en) | A method of producing IgG | |
JP6132839B2 (ja) | 多価免疫グロブリン濃縮物の製造方法 | |
CA2584407C (fr) | Procede permettant d'isoler l'haptoglobine | |
KR20000036002A (ko) | 혈장 단백질 함유 약제를 제조하는 방법 | |
US20220380439A1 (en) | Purification of fviii from plasma using silicon oxide adsorption | |
JP2024501025A (ja) | 免疫グロブリンgのプロセススケールでの単離のためのシステム及び方法 | |
CA3183021A1 (fr) | Procede d'obtention d'une composition comprenant une immunoglobuline m derivee du plasma humain | |
WO2024134608A1 (fr) | Procédé de purification de l'hémopexine faisant appel à la chromatographie en mode mixte | |
US20180305401A1 (en) | Processes for purifying proteins from plasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20210826 |
|
EEER | Examination request |
Effective date: 20210826 |
|
EEER | Examination request |
Effective date: 20210826 |
|
EEER | Examination request |
Effective date: 20210826 |
|
EEER | Examination request |
Effective date: 20210826 |
|
EEER | Examination request |
Effective date: 20210826 |